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http://dx.doi.org/10.1016/j.bgm.201
2214-0247/Copyright ª 2015, TaiwanAbstract This study aimed to elucidate whether CSN1S2 protein of goat’s milk was able to
inhibit pro-inflammatory cytokine [interleukin (IL)-17 and tumor necrosis factor (TNF)-a],
RAGE, and caspase-3 expression in rheumatoid arthritis (RA) rats. A total of 24 Wistar female
rats, were randomly assigned into four groups: control group (C), CSN1S2 protein of goat’s
milk group (CM), CFA-induced RA-rats group (RA), and the RA group treated by CSN1S2 protein
of goat’s milk (RAM). The severity of erythema and swelling in lower extremities were
counted by scoring. IL-17, TNF-a, RAGE, and caspase-3 expression in synovial membranes
were analyzed by confocal laser scanning microscopy (CLSM) and western blotting. Erythema
and swelling in the RA group was significantly attenuated by goat’s milk CSN1S2 (p < 0.05),
but did not reach the level in the control group (p < 0.05). The use of CLSM, CSN1S2 protein
of goat’s milk could decrease the TNF-a, caspase-3, and the number of hyperplasia cells in
comparison with the RA group (p < 0.05), to reach the level in the control group
(p > 0.05). Western blotting analysis showed that the expression of IL-17, RAGE, TNF-a,
and caspase-3 were higher in the RA group compared with the control group. CSN1S2 protein
of goat’s milk decreased RAGE and TNF-a expression, but increased the IL-17 and caspase-3
expression. In conclusion, CSN1S2 protein of goat’s milk decreased erythema, swelling, and
inflammation in lower extremities. The CSN1S2 protein of goat’s milk also decreased TNF-a
and RAGE expression in the synovial membrane of ankle joints. Unfortunately, CSN1S2 protein
of goat’s milk may induce the production of IL-17. Therefore CSN1S2 protein of goat’s milkt of Biology, Faculty of Sciences, University of Brawijaya, Jl. Veteran, Malang, 65145 East Java,
id, fatchiya@gmail.com (F. Fatchiyah).
to this work.
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arthritis.
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One of the autoimmune diseases that is characterized by
chronic inflammation due to various risk factors is rheu-
matoid arthritis (RA). The disease prognosis and develop-
ment are related to synovial joint inflammation, cartilage
destruction, and bone erosion.1 Proinflammatory cytokines
that may affect joint damage in RA is interleukin (IL)-17
which is produced by T-helper (Th)17. Previous studies
showed that IL-17 causes joint inflammation in mice
through intra-articular injection. Otherwise, blocking of IL-
17/IL-17R signaling may control the RA symptoms and pre-
vent the joint degradations.2 This fact indicates that every
compound that inhibits IL-17 production would be benefi-
cial in rheumatoid arthritis.
Rheumatoid arthritis patients have a high level of
advanced glycation end products (AGEs) in plasma and sy-
novial fluid.3,4 AGEs react with their receptors (RAGEs) to
induce oxidative stress. This reaction activates nuclear
factor kappa beta (NF-kB) which triggers the over-
expression of genes for cytokines, growth factors, and ad-
hesive molecules. Intracellular signal transduction
pathways, such as extracellular signal-regulated protein
kinase (ERK), the p38 mitogen-activated protein kinases
(p38MAPK), the c-Jun N-terminal kinase (JNK kinase),
transcription of cytokine gene, growth factor gene,
including tumor necrosis factor (TNF)-a or for apoptosis
pathway, and the NF-kB (nuclear factor-kB) pathway acti-
vated by AGE-RAGE interaction.5e7 This finding also in-
dicates that every substance that inhibits AGE-RAGE will
have beneficial effects to RA progression. In addition,
previous studies indicate that the modulation of synovial
fibroblast apoptosis (marked using caspase-3) may
contribute to the synovial hyperplasia and have beneficial
effects for rheumatod arthritis.8,9
Bioactive peptides from food proteins represent a source
of health enhancing components that may be incorporated
into functional foods and/or used as nutraceuticals.10 Milk
protein-derived bioactive peptides are health-enhancing
components that can be used to reduce the risk of dis-
ease or to enhance certain physiological functions.11 Casein
protein and electrophoretic casein fractions have been
shown to exhibit different biological activities, such as
immunomodulation.12 Our previous study reported that we
found specifically the alpha-S2 casein (CSN1S2) protein has
molecular weight (MW) 36 kDa only in goat milk which has
no band in bovine milk; we also determined this 36 kDa
contains eight peptides analyzed by matrix assisted laser
desorption ionization time-of-flight.13 Previous in vitro
study concluded that CSN1S2 protein of goat’s milk
(0.100 mg/L) inhibits the decrease of viability due to in-
creases in the proliferation of MC3T3E1 preosteoblast cells
due to methyl glyoxal exposure.14 As far as we known, thereis no study investigating the effect of CSN1S2 protein of
goat’s milk in rheumatoid arthritis. Therefore, this study
aimed to investigate whether CSN1S2 protein of goat’s milk
is able to inhibit clinical severity and modulate the IL-17,
RAGE, TNF-a, and caspase-3 expression of rheumatoid
arthritis rats.
Materials and methods
Animal
Twenty four, 12-week-old, male Wistar rats, weighing
250e300 g, were obtained from the Laboratory of Exper-
imental Animal, UPT LPPT, Gadjah Mada University,
Yogyakarta, Indonesia. The animals were acclimatized for
1 week in Biosains Laboratory, Brawijaya University,
Malang, Indonesia conditions prior to experimental pro-
cedure. They were exposed to a 12-hour light and 12-hour
dark cycles at room temperature (24C) and had free ac-
cess to standard laboratory chow or drinking water ad
libitum. After that, the animals were randomly divided
into four groups (n Z 6 each): control (untreated) group
(C), CSN1S2 protein of goat’s milk group (CM), rheumatoid
arthritis group (RA), and rheumatoid arthritis group
treated by CSN1S2 protein of goat’s milk (RAM). The
treatment with the CSN1S2 protein of goat’s milk was
performed for 60 days.
Rat adjuvant-induced arthritis model
Rat adjuvant-induced arthritis model was performed ac-
cording to previous studies with modification.15 Adjuvant-
induced arthritis in rats were established by a single sub-
cutaneous injection of 100 mL of Complete Freund’s Adju-
vant (CFA; SigmaeAldrich Inc., Saint Louis, Missouri, USA).
Fourteen days later, intradermal injection of 50 mL of FCA
(SigmaeAldrich Inc., Saint Louis, Missouri, USA) were per-
formed into the lower extremity. The treatment with the
CSN1S2 protein of goat’s milk was conducted 24 hours after
the last injection.
Preparation and administration of casein
Isolation of CSN1S2 protein was performed on fresh goat’s
milk. A 250-mL quantity of milk was heated to 40

C, glacial
acetic acid was added and then stirred until a precipitate
formed. The precipitate was separated by meshing with
nylon. The protein concentration was measured by Nano
Drop and stored at 20C if not immediately used. CSN1S2
protein was isolated from 36 kDa protein sequence from SDS
PAGE gel. CSN1S2 protein isolated from goat’s milk was
orally administrated by gavage at a dose of 2 mg/kg body
66 R.R. Bia et al.weight according to a previous study with dose
modification.16
Clinical sign of arthritis
The sign of arthritis was assessed by evaluation of erythema
and swelling in lower extremities. This assesment was
conducted by three independent evaluators. The severity
of arthritis in each of the two paws was graded in a scale of
0e4 according to established protocol and ranked as fol-
lows: 0 Z no evidence of erythema and swelling (normal);
1 Z erythema and mild swelling confined to the tarsals or
ankle joint; 2 Z erythema and mild swelling extending
from the ankle to the tarsals; 3 Z erythema and moderate
swelling extending from ankle to metatarsal joints; and
4 Z erythema and severe swelling encompass the ankle,
foot and digits, or ankylosis of the limb.17
Histopathological analysis
The rats were sacrificed at the end of the experiment, their
synovial membrane of the ankle joint were isolated and
fixed in 4% PFA. Afterwards, tissues were dehydrated with
ethanol (96%), then cleared using xylene, and infiltrated
using liquid paraffin at 56e57

C for 3 hours, the last
embedded with paraffin and sectioned with 4 mm thickness.
Histopathological profile of the ankle synovial membrane
was stained by hematoxylineeosin (HE). Deparafinization
using xylene, dehydration with alcohol series (absolute
ethanol, 90 until 70%), then slides were washed with
phosphate buffered saline (PBS) for 15 minutes. Thereafter
slides were first stained with hematoxylin then washed with
running water. Afterwards slides were stained with eosin
and washed with running water. Slides were dehydrated
again with 70% and 90% ethanol, each for 2 minutes, fol-
lowed by absolute ethanol. Then the slides were immersed
in xylene for 10 minutes, and then dried and covered with
Enthelan R (Merck, Darmstadt, Germany) then covered by
cover glasses. These slides were observed using Olympus
BX53 microscope (Olympus Corporation, Tokyo, Japan) with
CellsSens Standart software version 1.5 (Olympus Corpora-
tion, Tokyo, Japan) and evaluated by a pathology expert.
Double-labeling immunofluorescence staining
Immunofluorescence staining was conducted to determine
the IL-17, RAGE, TNF-a, and caspase-3 protein expression onTable 1 Body weight, daily intake, clinical scoring, and hyperp
Control CM
Body weight (g) 372.49  30.12 355.27  12.
Daily intake (g) 23.61  2.26 22.10  2.4
Scoring (unit) 0.00  0.00 0.00  0.0
Hyperplasia (%) 6.67  0.58 7.00  1.0
Data are presented as mean  SD.
*p < 0.05 in comparison with control group.
**p < 0.05 in comparison with CM group.
***p < 0.05 in comparison with RA group.
% Z percentage; CM Z CSN1S2 protein of goat’s milk group; g Z gra
group treated by CSN1S2 protein of goat’s milk.synovial membrane according to previous studies with little
modification.18 Slides were incubated with first primary anti
IL-17 rabbit (1:1000 dilution; Santa Cruz Biotechnology Inc.,
USA) and first of secondary mouse antirabbit IgG-FITC
(1:1500; Santa Cruz Biotechnology Inc., USA) for 1 hour
each in dark conditions. Slides were stained secondly with of
primary antiRAGE mouse monoclonal (1:1500 dilution; Santa
Cruz Biotechnology Inc., USA) antibodies and secondly with
secondary goat-anti mouse IgG-R (1:1500; Santa Cruz
Biotechnology Inc., USA) antibodies each for 1 hour in dark
conditions. By using a similar technique, we also performed
immunofluorescence staining for TNF-a and caspase-3
expression. To visualize and measure the IL-17, RAGE, TNF-
a, and caspase-3 expressions were analyzed using Olympus
confocal laser scanning microscopy (CLSM; Olympus Corpo-
ration, Tokyo, Japan). Slides were captured on three fields.
IL-17, RAGE, TNF-a, and caspase-3 expression were quanti-
fied with the Olympus FluoView software version 1.7a
(Olympus Corporation, Tokyo, Japan).
Immunoblotting of IL-17, RAGE, TNF-a, and
caspase-3
Protein (10 mg/mL) of synovial membrane was separated in
12.5% SDSepolyacrylamide gels electrophoresis and blotted
into a nitrocellulose membrane. Nonspecific protein-binding
sites were blocked by overnight incubation of 5% skimmilk in
PBS. The membrane was subsequently incubated overnight
at 4C with rabbit anti-IL17, mouse antiRAGE, rabbit
antiTNF-a, and mouse anticaspase-3 (Santa Cruz Biotech-
nology). The membranes were washed and incubated for
1e2 hours at room temperature with peroxides-labeled
polyclonal antirabbit IgG and antimouse IgG (KPL, Gai-
thersburg, Maryland, USA). The antigeneantibody com-
plexes were visualized with Western Blue Stabilized
Substrate (KPL, Gaithersburg, Maryland, USA). The reaction
was stopped by the addition of sterile aquadest. Membrane-
labeled was visualized by ChemiDoc Imaging (Bio-Rad Lab-
oratories Inc., Hercules, USA) and the intensity of specific
protein bands were counted by Quantity One software. (Bio-
Rad Laboratories Inc., Hercules, USA).
Ethics
This research has been approved by research ethics com-
mittee Faculty of Brawijaya University, Malang, East Java,
Indonesia (Registration number, KEP-90-UB).lasia in each group.
RA RAM
75 308.57  9.17* 319.80  32.45
3 22.21  3.15 22.21  3.15
0 4.00  0.0*,** 1.30  0.57*,**,***
0 25.67  2.08*,** 10.67  2.08***
m; RA Z rheumatoid arthritis group; RAM Z rheumatoid arthritis
Table 2 Expression of IL-17, TNF-a, RAGE, and caspase-3 in all experimental groups.
Control CM RA RAM
IL-17 (int/mm) 535.41  359.82 603.58  245.36 1196.09  354.89 724.33  813.24
TNF-a (int/mm) 144.27  21.07 161.54  23.72 720.62  80.30*,** 243.73  32.86***
RAGE (int/mm) 543.77  306.32 600.88  415.39 1163.95  441.26 643.64  554.32
Caspase-3 (int/mm) 213.85  30.95 251.22  53.81 543.18  85.83*,** 307.96  52.71***
Values are presented as mean  SD.
*p < 0.05 in comparison with control group.
**p < 0.05 in comparison with CM group.
***p < 0.05 in comparison with RA group.
CM Z CSN1S2 protein of goat’s milk group; IL-17 Z interleukin 17; int/mm Z intensity/micrometer; RA Z rheumatoid arthritis group;
RAGEZ receptor for advanced glycation end products; RAMZ rheumatoid arthritis group treated by CSN1S2 protein of goat’s milk; TNF-
a Z tumor necrosis factor-a.
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Data are presented as mean  SD and differences among
groups were analyzed using analysis of variance and Hon-
estly Significant Difference test using SPSS 16.0 statistical
package (SPSS Inc., Chicago, Illinois, USA). A p value <0.05
was considered statistically significant.Figure 1 Micrograph illustrating the expression of RAGE and IL-17
of RAGE was labeled with FITC staining (green), IL-17 was labele
CZ control group; CMZ CSN1S2 protein of goat’s milk group; HEZ
arthritis group; RAGE Z receptor for advanced glycation end pro
protein of goat’s milk.Results
Clinical sign of arthritis
Clinical severity of lower extremities in control and
experimental groups was measured by scoring, as given in
Table 1. The level of scoring was higher significantly in thein the synovial membrane of each group. Immunofluorescence
d with Rhodamine (red) (Magnification 400; bar is 30 mm).
hematoxylin eosin; IL-17Z interleukin-17; RAZ rheumatoid
ducts; RAM Z rheumatoid arthritis group treated by CSN1S2
68 R.R. Bia et al.RA group than the control group (p > 0.05). CSN1S2 protein
of goat’s milk significantly attenuated the erythema and
swelling degree compared with the RA group (p < 0.05), but
can not reach the level in the control group (p < 0.05).Body weight and intake
Table 1 also presented the body weight and level of intake
in each group. The body weight was lower significantly in
the RA group compared with the control group (p < 0.05),
but the daily quantity of intake was not significantly
different between the groups (p > 0.05).Hyperplasia cell
The number of hyperplasia cells in synovial membranes was
higher significantly in the RA group compared with the
control group (p > 0.05). Administration of CSN1S2 protein
of goat’s milk was able to decrease the number of hyper-
plasia cells compared with the RA group (p < 0.05), to
reach the level in the control group (p > 0.05), as seen in
Table 1.Figure 2 Micrograph illustrating the expression of TNF-a and ca
cence of TNF-a was labeled with FITC staining (green), caspase-3
30 mm). C Z control group; CM Z CSN1S2 protein of goat’s
RA Z rheumatoid arthritis group; RAM Z rheumatoid arthritis gro
necrosis factor-a.IL-17, RAGE, TNF-a, and caspase-3 expression
The expression of IL-17, RAGE, TNF-a, and caspase-3 in the
control and experimental groups was presented in Table 2,
and Figs. 1 and 2. Confocal micrographs show that the IL-17
and RAGE expression were not significant in all groups
(p > 0.05). A confocal micrograph of TNF-a and caspase-3
was higher significantly in RA compared with control
group (p < 0.05). Indeed, CSN1S2 protein of goat’s milk
reduces the level of TNF-a and caspase-3 significantly than
the RA group (p < 0.05), to reach similar levels at a control
group (p > 0.05). Western blotting analysis showed that the
expression of IL-17, RAGE, TNF-a, and caspase-3 were
higher in the RA group compared with the control group.
CSN1S2 protein of goat’s milk decrease RAGE and TNF-a
expression, but increase the IL-17 and caspase-3 expres-
sion, as seen in Fig. 3.
Histopathological of synovial membrane
Synovial membrane of lower extremities in each group are
presented in Fig. 4. Pathological section from synovial
membranes of control (untreated) rats show lipid cells
proliferation with minimal connective tissue. Thespase-3 in synovial membrane of each group. Immunofluores-
was labeled with Rhodamine (red) (Magnification 400; bar is
milk group; CSP-3 Z caspase-3; HE Z hematoxylin eosin;
up treated by CSN1S2 protein of goat’s milk; TNF-a Z tumor
Figure 3 (A) Immunoblotting; (B) density and intensity level of IL-17; (C) density and intensity level of TNF-a; (D) density and
intensity level of RAGE; and (E) density and intensity level of caspase-3 in synovial membrane. C Z control group; CM Z CSN1S2
protein of goat’s milk group; IL-17Z interleukin-17; RAZ rheumatoid arthritis group; RAGEZ receptor for advanced glycation end
products; RAM Z rheumatoid arthritis group treated by CSN1S2 protein of goat’s milk; TNF-a Z tumor necrosis factor-a.
Figure 4 Micrograph illustrating the histopathology of synovial membrane of lower extremity in each group; (A) synovial
membrane of control (untreated) rats show lipid cells proliferation (red arrow) with minimal connective tissue (blue arrow); (B)
CSN1S2 protein of goat’s milk in control rats induces the proliferation of lipid cells in larger size (red arrow) accompanied by growth
of fibrous connective tissue (blue arrow) in separated morpohology; (C) in the RA group, we found the dominancy of connective
tissue (blue arrow), minimal lipid cells (red arrow) and massive inflammatory cells (green arrow); and (D) CSN1S2 protein of goat’s
milk induces the connective tissue hardening and minimal inflammation/granulation and lytic process in connective tissue in RA
group. Hematoxylin eosin staining (Magnification 40; bar is 2 mm).
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induces the proliferation of lipid cells of a larger size
accompanied by growth of fibrous connective tissue in
separated morpohology. In the RA group we found the
dominancy of connective tissue, minimal lipid cells, and
massive inflammatory cells. CSN1S2 protein of goat’s milk
induces the connective tissue hardening and minimal
inflammation/granulation and lytic process in connective
tissue in the RA group.Discussion
The chronic soft tissue inflammation will determine the
disease progression of RA.1 In this study we used Freund’s
complete adjuvant to induce the arthritis process. The
inactivated mycobacterium is the main active substance in
Freund’s complete adjuvant and has been conventionally
used to induce typical arthritis in rats.19
Previous studies stated that malnutrition is the estab-
lished symptom in RA, in this study we found the level of
body weight was significantly decreased in the RA group
compared with the control group (p < 0.05) probably
because of overproduction of TNF-a and IL-1.20 The nutri-
tional status of RA patients was compromised despite
adequate intake.21 The increased production of inflamma-
tory cytokines affects the energy metabolism and protein
metabolism, leading to a loss of body cell mass, namely as
rheumatoid cachexia.22
This study showed that in the RA group, we found the
dominancy of connective tissue with minimal lipid cells.
Conversely, synovial membrane of control (untreated) rats
show lipid cell proliferation with minimal connective tissue.
Our finding suggested that the CFA model established in this
study was successful and stable. However, in RAM groups, we
found the connective tissue hardest and minimal inflamma-
tion/granulation and lytic process in connective tissue,
which indicated that the CSN1S2 protein of goat’s milk may
induce the remodelling and decrease of inflammation in the
synovial membrane.We found the level of scoring was higher
significantly in the RA group than that of the control group
(p < 0.05), and CSN1S2 protein of goat’s milk significantly
reduced both parameters compared with the RA group
(p < 0.05). This finding indicates that the CSN1S2 protein of
goat’s milk is able to act as an anti-inflammatory to inhibit
the erythema and swelling in the lower extremity.
Our confocal data show that the expression of IL-17 and
RAGE were insignificant between groups (p > 0.05). West-
ern blotting data showed that the expression of IL-17,
RAGE, TNF-a, and caspase-3 were higher in the RA group
compared with the control group. Previous arthritis mouse
models that were induced by collagen showed that there
were two stages; the early stage was dependent on the
level of TNF stage and the advanced stage disease was
mostly performed by IL-17.23 We propose that our model is
novel for the overlapping stage in rheumatoid arthritis. The
effect of CSN1S2 protein of goat’s milk on erythema,
swelling, and inflammation may not be IL-17 dependent,
but dependent on RAGE and TNF-a. We hypothesized that
the CSN1S2 protein of the goat may induce IL-17 production
of Th17 cells. However, our CLSM and Western blotting of
caspase-3 indicates that the CSN1S2 protein of goat’s milkincreases the enzymatic activity of caspase-3. This
increasing may be involved in the remodelling of the sy-
novial membrane. This finding supported by our other data
that administration of CSN1S2 protein of goat’s milk is able
to decrease the number of hyperplasia cells in comparison
with the RA group (p < 0.05), to reach the level in the
control group (p > 0.05).
In conclusion, CSN1S2 protein of goat’s milk decrease
erythema, swelling, and inflammation in lower extremities.
CSN1S2 protein of goat’s milk also decreased TNF-a and
RAGE expression in synovial membranes of ankle joints.
Unfortunately, CSN1S2 protein of goat’s milk may induce
the production of IL-17.
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